| Literature DB >> 33081775 |
Andreas Niedermaier1, Anna Freiberg2, Daniel Tiller3, Andreas Wienke2, Amand Führer2.
Abstract
BACKGROUND: Asylum seekers are a vulnerable group with special needs in health care due to their migration history and pre-, peri- and postmigratory social determinants of health. However, in Germany access to health care is restricted for asylum seekers by law and administrative regulations.Entities:
Keywords: Asylum seekers; Claims data; Health care expenditures; Health care utilization; Restricted access; Secondary data analysis
Mesh:
Year: 2020 PMID: 33081775 PMCID: PMC7576695 DOI: 10.1186/s12913-020-05811-4
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Demographic characteristics of the study population
| Male | Female | All | ||||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| | 154 | 3.75 | 158 | 3.85 | 312 | 7.6 |
| | 118 | 2.87 | 119 | 2.9 | 237 | 5.77 |
| | 110 | 2.68 | 64 | 1.56 | 174 | 4.24 |
| | 344 | 8.38 | 92 | 2.24 | 436 | 10.62 |
| | 655 | 15.95 | 134 | 3.26 | 789 | 19.21 |
| | 601 | 14.63 | 164 | 3.99 | 765 | 18.63 |
| | 424 | 10.32 | 124 | 3.02 | 548 | 13.34 |
| | 249 | 6.06 | 95 | 2.31 | 344 | 8.38 |
| | 154 | 3.75 | 48 | 1.17 | 202 | 4.92 |
| | 113 | 2.75 | 32 | 0.78 | 145 | 3.53 |
| | 42 | 1.02 | 25 | 0.61 | 67 | 1.63 |
| | 17 | 0.41 | 20 | 0.49 | 37 | 0.9 |
| | 9 | 0.22 | 11 | 0.27 | 20 | 0.49 |
| | 14 | 0.34 | 17 | 0.41 | 31 | 0.75 |
| | 3004 | 73.14 | 1103 | 26.86 | 4107 | 100 |
| | 1461 | 35.57 | 496 | 12.08 | 1957 | 47.65 |
| | 244 | 5.94 | 110 | 2.68 | 354 | 8.62 |
| | 115 | 2.8 | 65 | 1.58 | 180 | 4.38 |
| | 109 | 2.65 | 64 | 1.56 | 173 | 4.21 |
| | 141 | 3.43 | 27 | 0.66 | 168 | 4.09 |
| | 88 | 2.14 | 33 | 0.8 | 121 | 2.95 |
| | 101 | 2.46 | 15 | 0.37 | 116 | 2.82 |
| | 94 | 2.29 | 7 | 0.17 | 101 | 2.46 |
| | 49 | 1.19 | 49 | 1.19 | 98 | 2.39 |
| | 61 | 1.49 | 35 | 0.85 | 96 | 2.34 |
| | 26 | 0.63 | 11 | 0.27 | 37 | 0.9 |
| | 515 | 12.54 | 191 | 4.65 | 706 | 17.19 |
| | 3004 | 73.14 | 1103 | 26.86 | 4107 | 100 |
| | 249 | 6.06 | 125 | 3.04 | 374 | 9.11 |
| | 591 | 14.39 | 300 | 7.3 | 891 | 21.69 |
| | 375 | 9.13 | 139 | 3.38 | 514 | 12.52 |
| | 467 | 11.37 | 103 | 2.51 | 570 | 13.88 |
| | 360 | 8.77 | 45 | 1.1 | 405 | 9.86 |
| | 137 | 3.34 | 47 | 1.14 | 184 | 4.48 |
| | 132 | 3.21 | 47 | 1.14 | 179 | 4.36 |
| | 693 | 16.87 | 297 | 7.23 | 990 | 24.11 |
| | 3004 | 73.14 | 1103 | 26.84 | 4107 | 100 |
Fig. 1Estimated one-year prevalence of having at least one contact with any outpatient physician
Fig. 2Most commonly consulted ambulatory specialties with estimated one-year prevalence having at least one contact
One-year prevalence of diagnoses by chapters of the ICD-10 (with 95% confidence intervals)
| Diagnosis groups | One-year prevalence | ||
|---|---|---|---|
| Chapter ICD-10 | % of men [95%-CI] | % of women [95%-CI] | % of all [95%-CI] |
| 1: Certain infectious and parasitic diseases | 19.1 [17.0–21.6] | 28.0 [23.9–32.6] | 21.6 [19.6–23.7] |
| 2: Neoplasms | 2.6 [1.9–3.6] | 10.9 [8.4–14.1] | 4.9 [4.0–6.0] |
| 3: Diseases of the blood, blood-forming organs and certain disorders inv. the immune mechanism | 2.2 [1.5–3.2] | 12.0 [9.4–15.4] | 4.8 [3.9–6.0] |
| 4: Endocrine, nutritional and metabolic diseases | 5.4 [4.2–6.8] | 17.9 [14.6–21.8] | 8.7 [7.5–10.2] |
| 5: Mental and behavioural disorders | 11.8 [10.1–13.7] | 21.1 [17.6–25.1] | 14.2 [12.7–16.0] |
| 6: Diseases of the nervous system | 7.2 [5.9–8.8] | 10.8 [8.3–14.0] | 8.1 [6.9–9.6] |
| 7: Diseases of the eye and adnexa | 9.8 [8.2–11.6] | 14.2 [11.2–17.9] | 11.0 [9.6–12.7] |
| 8: Diseases of the ear and mastoid process | 4.4 [3.4–5.7] | 8.8 [6.4–11.9] | 5.6 [4.6–6.9] |
| 9: Diseases of the circulatory system | 5.2 [4.2–6.6] | 12.0 [9.2–15.4] | 7.1 [6.0–8.5] |
| 10: Diseases of the respiratory system | 24.5 [22.2–27.1] | 36.1 [31.9–40.8] | 27.6 [25.5–29.8] |
| 11: Diseases of the digestive system | 16.9 [14.8–19.3] | 24.2 [20.6–28.4] | 18.8 [17.0–20.8] |
| 12: Diseases of the skin and subcutaneous tissue | 14.9 [13.1–17.0] | 25.3 [21.5–29.7] | 17.7 [15.9–19.6] |
| 13: Diseases of the musculoskeletal system and connective tissue | 21.0 [18.8–23.5] | 24.8 [21.2–29.0] | 22.0 [20.0–24.0] |
| 14: Diseases of the genitourinary system | 7.7 [6.3–9.3] | 39.9 [35.5–44.6] | 16.0 [14.3–17.8] |
| 15: Pregnancy, childbirth and the puerperium | – | 15.9 [13.0–19.5] | 4.2 [3.4–5.3] |
| 16: Certain conditions originating in the perinatal period | 0.3 [0.1–0.5] | 0.4 [0.1–1.1] | 0.3 [0.2–0.5] |
| 17: Congenital malformations, deformations and chromosomal abnormalities | 2.2 [1.5–3.3] | 4.7 [3.1–7.0] | 2.9 [2.2–3.8] |
| 18: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | 27.9 [25.4–30.6] | 54.6 [49.8–59.5] | 34.9 [32.5–37.3] |
| 19: Injury, poisoning and certain other consequences of external causes | 16.6 [14.5–18.9] | 13.0 [10.1–16.5] | 15.6 [13.9–17.5] |
| 20: External causes of morbidity and mortality | 0.3 [0.1–0.9] | 0.3 [0.0–2.3] | 0.3 [0.1–0.8] |
| 21: Factors influencing health status and contact with health services | 12.2 [10.5–14.2] | 52.4 [47.6–57.4] | 22.7 [20.7–24.8] |
| 22: Codes for special purposes | 6.8 [5.5–8.5] | 15.0 [12.1–18.6] | 8.9 [7.6–10.3] |
Most commonly prescribed drug groups with percentages of all prescriptions and estimated one-year prevalences of receiving at least one prescription
| Prescribed drugs | Proportion | One-year prevalence | |||
|---|---|---|---|---|---|
| Code | Group name | % of all prescriptions | % of men [95%-CI] | % of women [95%-CI] | % of all [95%-CI] |
| M01 | Anti-inflammatory and antirheumatic products | 15.9 | 33.2 [30.5–36.1] | 41.1 [36.5–46.0] | 35.3 [33.0–37.8] |
| J01 | Antibacterials for systemic use | 7.0 | 14.6 [12.7–16.7] | 28.5 [24.5–33.1] | 18.3 [16.5–20.3] |
| N02 | Analgesics | 6.3 | 14.0 [12.1–16.1] | 25.0 [21.1–29.5] | 17.1 [15.3–19.1] |
| A02 | Drugs for acid related disorders | 6.3 | 14.6 [12.6–16.8] | 16.2 [13.2–19.8] | 14.9 [13.3–16.7] |
| R05 | Cough and cold preparations | 5.7 | 7.2 [6.0–8.7] | 14.2 [11.3–17.7] | 9.1 [7.9–10.5] |
| R01 | Nasal preparations | 5.6 | 7.2 [5.9–8.9] | 16.2 [13.2–19.8] | 9.6 [8.3–11.1] |
| N06 | Psychoanaleptics | 4.6 | 3.8 [2.9–5.0] | 7.8 [5.6–10.8] | 4.9 [3.9–6.1] |
| N05 | Psycholeptics | 4.5 | 2.6 [1.8–3.6] | 6.3 [4.3–9.2] | 3.6 [2.8–4.7] |
| J04 | Antimycobacterials | 3.1 | 1.6 [1.0–2.5] | 1.2 [0.6–2.5] | 1.5 [1.0–2.2] |
| D07 | Corticosteroids, dermatological preparations | 3.1 | 7.0 [5.7–8.7] | 10.8 [8.1–14.2] | 8.1 [6.8–9.5] |
| J07 | Vaccines | 2.6 | 3.8 [2.8–5.2] | 8.4 [6.0–11.7] | 5.1 [4.1–6.4) |
Fig. 3Proportions of costs per sector